Biopredictive tools for the development of injectable drug products

被引:6
作者
Villa Nova, Monica [1 ]
Gan, Kennard [2 ]
Wacker, Matthias G. [2 ]
机构
[1] Univ Estadual Maringa, Dept Pharm, Maringa, Parana, Brazil
[2] Natl Univ Singapore, Dept Pharm, Singapore, Singapore
基金
新加坡国家研究基金会;
关键词
Biopredictive performance assay; biorelevant dissolution testing; depot injectable suspension; Dissolution; drug release; intravenous (IV); liposomes; Long-acting injectables (LAI); Physiologically based biopharmaceutics modeling (PBBM); Physiologically based pharmacokinetic modeling (PBPK); subcutaneous (SC) microparticle formulations; VITRO RELEASE MODELS; IN-VIVO PERFORMANCE; PLGA MICROSPHERES; PREDICTING BIOAVAILABILITY; DISSOLUTION; INJECTION; KINETICS; DELIVERY; PLASMA; PHARMACOKINETICS;
D O I
10.1080/17425247.2022.2081682
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Biopredictive release tests are commonly used in the evaluation of oral medicines. They support decision-making in formulation development and allow predictions of the expected in-vivo performances. So far, there is limited experience in the application of these methodologies to injectable drug products. Areas covered Parenteral drug products cover a variety of dosage forms and administration sites, including subcutaneous, intramuscular, and intravenous injections. In this area, developing biopredictive and biorelevant methodologies often confronts us with unique challenges and knowledge gaps. Here, we provide a formulation-centric approach and explain the key considerations and workflow when designing biopredictive assays. Also, we outline the key role of computational methods in achieving clinical relevance and put all considerations into context using liposomal nanomedicines as an example. Expert opinion Biopredictive tools are the need of the hour to exploit the tremendous opportunities of injectable drug products. A growing number of biopharmaceuticals such as peptides, proteins, and nucleic acids require different strategies and a better understanding of the influences on drug absorption. Here, our design strategy must maintain the balance between robustness and complexity required for effective formulation development.
引用
收藏
页码:671 / 684
页数:14
相关论文
共 131 条
[1]   Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report [J].
Abend, Andreas ;
Heimbach, Tycho ;
Cohen, Michael ;
Kesisoglou, Filippos ;
Pepin, Xavier ;
Suarez-Sharp, Sandra .
AAPS JOURNAL, 2018, 20 (03)
[2]   Formation of protein corona in vivo affects drug release from temperature-sensitive liposomes [J].
Al-Ahmady, Zahraa S. ;
Hadjidemetriou, Marilena ;
Gubbins, James ;
Kostarelos, Kostas .
JOURNAL OF CONTROLLED RELEASE, 2018, 276 :157-167
[3]  
Alwawi Eihab A, 2008, Ther Clin Risk Manag, V4, P345
[4]   Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial [J].
Amanat, Man ;
Majmaa, Anahita ;
Zarrabi, Morteza ;
Nouri, Masoumeh ;
Akbari, Masood Ghahvechi ;
Moaiedi, Ali Reza ;
Ghaemi, Omid ;
Zamani, Fatemeh ;
Najafi, Sharif ;
Badv, Reza Shervin ;
Vosough, Massoud ;
Hamidieh, Amir Ali ;
Salehi, Mona ;
Montazerlotfelahi, Hadi ;
Tavasoli, Ali Reza ;
Heidari, Morteza ;
Mohebi, Hossein ;
Fatemi, Ali ;
Garakani, Amir ;
Ashrafi, Mahmoud Reza .
STEM CELL RESEARCH & THERAPY, 2021, 12 (01)
[5]   The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations [J].
Anderson, M ;
Omri, A .
DRUG DELIVERY, 2004, 11 (01) :33-39
[6]   Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments [J].
Astashkina, Anna ;
Grainger, David W. .
ADVANCED DRUG DELIVERY REVIEWS, 2014, 69 :1-18
[7]   Randomized Clinical Trial of Intraosseous Methylprednisolone Injection for Acute Pulpitis Pain [J].
Bane, Khaly ;
Charpentier, Emmanuel ;
Bronnec, Francois ;
Descroix, Vianney ;
Gaye-N'diaye, Fatou ;
Kane, Abdoul Wahabe ;
Toledo, Rafael ;
Machtou, Pierre ;
Azerad, Jean .
JOURNAL OF ENDODONTICS, 2016, 42 (01) :2-7
[8]   Impact of product design parameters on in vitro release from intrauterine systems [J].
Bao, Quanying ;
Zou, Yuan ;
Wang, Yan ;
Choi, Stephanie ;
Burgess, Diane J. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 578
[9]   Optimizing novel implant formulations for the prolonged release of biopharmaceuticals using in vitro and in vivo imaging techniques [J].
Beyer, Susanne ;
Xie, Li ;
Schmidt, Mike ;
de Bruin, Natasja ;
Ashtikar, Mukul ;
Rueschenbaum, Sabrina ;
Lange, Christian M. ;
Vogel, Vitali ;
Maentele, Werner ;
Parnham, Michael J. ;
Wacker, Matthias G. .
JOURNAL OF CONTROLLED RELEASE, 2016, 235 :352-364
[10]   Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with DoxilA® or CaelyxA® in advanced ovarian cancer [J].
Bhowmik, Shravanti ;
Bhowmick, Subhas ;
Maiti, Kuntal ;
Chakra, Amaresh ;
Shahi, Pradeep ;
Jain, Deepak ;
Rajamannar, Thennati .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (03) :521-532